Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Successive Doses vs Single Dose of GnRH Agonist to Trigger Ovulation in Hyper-responders Undergoing IVF
NCT07569315Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
- Sponsor
- Bedaya Hospital
- Modality
- Peptides, Small Molecules
- Drugs
- triptorelin
- Conditions
- infertility
01
Overview
Phase 2, randomised trial of triptorelin in infertility (2 arms), sponsored by Bedaya Hospital. Primary endpoint: Metaphase-II oocytes rate. Planned start Jun 2026; status: not yet recruiting.
02
Design
2 arms- Study design
- Randomized
Successive doses GnRH agonist
Three successive doses of GnRH agonist are administered 36, 24 and 12 hours before oocyte retrieval
Single dose GnRH agonist
A single dose of GnRH agonist is administered 36 hours before oocyte retrieval
03
Who it enrols
Women undergoing a GnRH antagonist IVF cycle who are hyper-responders to ovulation induction, excluding those with hypogonadotrophic hypogonadism, endometriosis, or a history of recurrent abortion.
04
Endpoints
Primary
Metaphase-II oocytes rate
Secondary
Clinical pregnancy rate
Ongoing pregnancy Rate
Beyond the preview
Go deeper on NCT07569315.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07569315.